Influenza Diagnostics Market by Test type (Molecular (RT-PCR,LAMP, NASBA), Traditional (Viral Culture, Direct Fluorescent Antibody, Rapid Influenza Detection Tests, Serological Assays)), End user (Hospital, Clinical Laboratories) - Global Forecast to 2025

インフルエンザ診断の世界市場予測:テスト種類別(分子型(RT-PCR、LAMP、NASBA)、従来型(ウイルス培養、直接蛍光抗体、インフルエンザ迅速検査、血清アッセイ))、エンドユーザー別(病院、臨床検査室)

◆タイトル:Influenza Diagnostics Market by Test type (Molecular (RT-PCR,LAMP, NASBA), Traditional (Viral Culture, Direct Fluorescent Antibody, Rapid Influenza Detection Tests, Serological Assays)), End user (Hospital, Clinical Laboratories) - Global Forecast to 2025
◆商品コード:BT 5027
◆調査・発行会社:MarketsandMarkets
◆発行日:2020年4月30日
◆ページ数:127
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD4,950 ⇒換算¥514,800見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥691,600見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥847,600見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

MarketsandMarkets社はインフルエンザ診断の世界市場が、2020年695百万ドルから2025年1,012百万ドルまで、年平均7.8%成長すると予測しています。本調査レポートでは、インフルエンザ診断の世界市場を広く調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場動向、検査種類別(分子型、従来型、その他)分析、エンドユーザー別(病院、臨床検査室、その他)分析、地域別分析、競争状況、企業概要などを含め、今後の方向性を提示しています。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場動向
・インフルエンザ診断の世界市場:検査種類別(分子型、従来型、その他)
・インフルエンザ診断の世界市場:エンドユーザー別(病院、臨床検査室、その他)
・インフルエンザ診断の世界市場:地域別
・競争状況
・企業概要

“The increasing prevalence of influenza, growth in research funding for influenza diagnostics, and the rising demand for faster diagnosis are expected to drive the overall growth of the influenza diagnostic market.”
The influenza diagnostic market is expected to grow from USD 695 million in 2020 to USD 1,012 million by 2025, at a CAGR of 7.8% during the forecast period. The major factors driving the growth of this market include increasing prevalence of influenza, growth in research funding for influenza diagnostics, and the rising demand for faster diagnosis are expected to drive the overall growth of the influenza diagnostic market.

“The traditional diagnostic segment commanded the largest share of the market in 2019.”
On the basis of test type, the market is broadly segmented into traditional diagnostic tests and molecular diagnostic tests. The RIDT segment accounted for the largest share of the influenza diagnostics market for traditional diagnostic tests of the influenza diagnostic market in 2019. The large share of this segment can be attributed to increased adoption of cost-effective and faster RIDT as a first line of diagnosis and screening process have been increased among the end-users. This is a major factor responsible for the largest share of the RIDT market.

“The hospitals segment commanded the largest share of the influenza diagnostic market in 2019.”
Based on end user, the influenza diagnostic market has been categorized into hospitals, clinical laboratories, and other end user. The hospitals segment commanded the largest share of the market in 2019. The large number of minimally invasive surgical procedures performed in hospitals due to the presence of highly skilled healthcare professionals is a major factor driving market growth.
“The Asia Pacific region to register the highest growth in the global MIS instruments market during the forecast period.”
The Asia Pacific is estimated to grow at the highest CAGR during the forecast period. Influenza disease diagnostics is commonly carried out in hospitals, as it is complex in nature and requires technologically advanced product, this is the major factor driving the growth of this segment.

In-depth interviews were conducted with chief executive officers (CEOs), marketing directors, other directors, and executives from various key organizations operating in the MIS instruments market.
• By Respondent Type: Supply Side (70%) and Demand Side (30%)
• By Designation: Managers (55%), CXOs (20%), and Executives (25%)
• By Region: North America (50%), Europe (20%), APAC (20%), and RoW (10%)

The influenza diagnostic market comprises major players such as Hoffmann-La Roche AG (Switzerland), Quidel Corporation (US), Thermo Fisher Scientific Inc. (US), Abbott Laboratories, Inc. (US), and Hologic Inc. (US). The study includes an in-depth competitive analysis of these key players in the influenza diagnostic market, along with their company profiles, recent developments, and key market strategies.

Research Coverage:
The market study covers the influenza diagnostic market across various segments. It aims at estimating the market size and the growth potential of this market across different segments based on test type, end user, and region. The study also includes an in-depth competitive analysis of the key players in the market, along with their company profiles, key observations related to their product and business offerings, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants in this market and provide information on the closest approximations of the revenue numbers for the overall influenza diagnostic market and its subsegments. This report will help stakeholders to understand the competitive landscape, to gain more insights so as to better position their businesses, and to plan suitable go-to-market strategies. The report will also help stakeholders to understand the pulse of the market and provide information on the key market drivers, restraints, opportunities, and challenges.

【レポートの目次】

1 INTRODUCTION (Page No. – 15)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS

2 RESEARCH METHODOLOGY (Page No. – 18)
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.1.3 DATA TRIANGULATION
2.2 MARKET ESTIMATION METHODOLOGY
2.3 MARKET GROWTH RATE PROJECTIONS
2.4 RESEARCH ASSUMPTIONS

3 EXECUTIVE SUMMARY (Page No. – 24)

4 PREMIUM INSIGHTS (Page No. – 26)
4.1 INFLUENZA DIAGNOSTICS MARKET OVERVIEW
4.2 NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET SHARE, BY TEST TYPE & COUNTRY (2019)
4.3 INFLUENZA DIAGNOSTICS MARKET SHARE, BY END USER (2019)

5 MARKET OVERVIEW (Page No. – 28)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing prevalence of influenza
5.2.1.2 Growth in influenza research
5.2.1.3 Rising demand for rapid disease diagnosis
5.2.2 RESTRAINTS
5.2.2.1 Variability in test sensitivity and specificity
5.2.2.2 Stringent regulatory framework
5.2.2.3 Rising healthcare costs
5.2.3 OPPORTUNITIES
5.2.3.1 Advancements in genomic and proteomic technologies
5.2.3.2 Significant growth prospects in developing countries
5.2.4 CHALLENGES
5.2.4.1 Lack of skilled professionals
5.3 THE IMPACT OF COVID-19 OUTBREAK ON THE GROWTH OF INFLUENZA DIAGNOSTICS MARKET
5.3.1 SIMILARITIES IN INFLUENZA AND COVID-19 SYMPTOMS
5.3.2 WHO RECOMMENDATIONS FOR THE CO-TESTING OF COVID-19 AND OTHER RESPIRATORY PATHOGENS, INCLUDING INFLUENZA AND RSV
5.3.3 INCREASED ADOPTION OF THE INFLUENZA VACCINE (FLU SHOT) IN THE HEALTHCARE SYSTEM
5.3.4 INCREASING FOCUS OF DIAGNOSTIC MANUFACTURERS ON THE DEVELOPMENT OF NEW COVID-19 TESTS

6 INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE (Page No. – 34)
6.1 INTRODUCTION
6.2 TRADITIONAL DIAGNOSTIC TESTS
6.2.1 RIDT
6.2.1.1 RIDT tests are widely used owing to their ease of use and rapid interpretability of results
6.2.2 VIRAL CULTURE
6.2.2.1 Wide use of viral culture as a confirmatory test to ensure the results of RIDT to drive market growth
6.2.3 DFA
6.2.3.1 Adoption of DFA tests is increasing due to their higher sensitivity as compared to RIDT
6.2.4 SEROLOGICAL ASSAYS
6.2.4.1 Development of lab-on-chip-based multiplex assays to support market growth
6.3 MOLECULAR DIAGNOSTIC TESTS
6.3.1 RT-PCR
6.3.1.1 Ability of RT-PCR to distinguish between influenza A and B viruses driving its adoption in clinical settings
6.3.2 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS
6.3.2.1 TRANSCRIPTION-MEDIATED AMPLIFICATION-BASED ASSAYS
6.3.2.1.1 TMA accounts for the largest share of the INAAT market
6.3.2.2 LOOP-MEDIATED ISOTHERMAL AMPLIFICATION-BASED ASSAYS
6.3.2.2.1 Rapidity, stability, and sensitivity have driven the use of LAMP
6.3.2.3 NUCLEIC ACID SEQUENCE-BASED AMPLIFICATION TESTS
6.3.2.3.1 NASBA is highly preferred in hospital and clinical settings as it reduces the need for additional reverse transcription steps
6.3.2.4 OTHER INAAT TESTS
6.3.3 OTHER MOLECULAR TESTS

7 INFLUENZA DIAGNOSTICS MARKET, BY END USER (Page No. – 52)
7.1 INTRODUCTION
7.2 HOSPITALS
7.2.1 HOSPITALS ACCOUNTED FOR THE LARGEST SHARE OF THE MARKET IN 2019
7.3 CLINICAL LABORATORIES
7.3.1 ADVANTAGES OFFERED BY CLINICAL LABORATORIES IN TERMS OF SERVICE COSTS AND TURNAROUND TIME TO SUPPORT MARKET GROWTH
7.4 OTHER END USERS

8 INFLUENZA DIAGNOSTICS MARKET, BY REGION (Page No. – 58)
8.1 INTRODUCTION
8.2 NORTH AMERICA
8.2.1 US
8.2.1.1 The US dominated the North American market in 2019
8.2.2 CANADA
8.2.2.1 Government initiatives and technological advancements in diagnostic techniques to support market growth
8.3 EUROPE
8.3.1 FRANCE
8.3.1.1 Supportive government policies drive market growth in France
8.3.2 UK
8.3.2.1 Frequent influenza outbreaks in the UK to boost the growth of the influenza diagnostics market
8.3.3 ROE
8.4 ASIA PACIFIC
8.4.1 INCREASING HEALTHCARE EXPENDITURE AND RISING AWARENESS INDICATE FAVORABLE PROSPECTS FOR MARKET GROWTH
8.5 REST OF THE WORLD

9 COMPETITIVE LANDSCAPE (Page No. – 82)
9.1 INTRODUCTION
9.2 MARKET RANKING ANALYSIS, 2019
9.3 COMPETITIVE LEADERSHIP MAPPING
9.3.1 VISIONARY LEADERS
9.3.2 INNOVATORS
9.3.3 DYNAMIC DIFFERENTIATORS
9.3.4 EMERGING COMPANIES
9.4 COMPETITIVE SCENARIO
9.4.1 KEY PRODUCT APPROVALS
9.4.2 KEY ACQUISITIONS

10 COMPANY PROFILES (Page No. – 86)
10.1 F. HOFFMANN-LA ROCHE AG
10.1.1 BUSINESS OVERVIEW
10.1.2 PRODUCTS OFFERED
10.1.3 MNM VIEW
10.2 QUIDEL CORPORATION
10.2.1 BUSINESS OVERVIEW
10.2.2 PRODUCTS OFFERED
10.2.3 RECENT DEVELOPMENTS
10.2.4 MNM VIEW
10.3 THERMO FISHER SCIENTIFIC, INC.
10.3.1 BUSINESS OVERVIEW
10.3.2 PRODUCTS OFFERED
10.3.3 MNM VIEW
10.4 ABBOTT LABORATORIES, INC.
10.4.1 BUSINESS OVERVIEW
10.4.2 PRODUCTS OFFERED
10.4.3 RECENT DEVELOPMENTS
10.5 HOLOGIC, INC.
10.5.1 BUSINESS OVERVIEW
10.5.2 PRODUCTS OFFERED
10.5.3 RECENT DEVELOPMENTS
10.6 BECTON, DICKINSON AND COMPANY
10.6.1 BUSINESS OVERVIEW
10.6.2 PRODUCTS OFFERED
10.6.3 RECENT DEVELOPMENTS
10.7 DANAHER CORPORATION
10.7.1 BUSINESS OVERVIEW
10.7.2 PRODUCTS OFFERED
10.7.3 RECENT DEVELOPMENTS
10.8 DIASORIN SA
10.8.1 BUSINESS OVERVIEW
10.8.2 PRODUCTS OFFERED
10.9 MERIDIAN BIOSCIENCE
10.9.1 BUSINESS OVERVIEW
10.9.2 PRODUCTS OFFERED
10.9.3 RECENT DEVELOPMENTS
10.1 LUMINEX CORPORATION
10.10.1 BUSINESS OVERVIEW
10.10.2 PRODUCTS OFFERED
10.11 BIOMÉRIEUX SA
10.11.1 BUSINESS OVERVIEW
10.11.2 PRODUCTS OFFERED
10.11.3 RECENT DEVELOPMENTS
10.12 GENMARK DIAGNOSTICS, INC.
10.12.1 BUSINESS OVERVIEW
10.12.2 PRODUCTS OFFERED
10.12.3 RECENT DEVELOPMENTS
10.13 SIEMENS HEALTHINEERS
10.13.1 BUSINESS OVERVIEW
10.13.2 PRODUCTS OFFERED
10.13.3 RECENT DEVELOPMENTS
10.14 TECAN TRADING
10.14.1 BUSINESS OVERVIEW
10.14.2 PRODUCTS OFFERED
10.15 SEKISUI DIAGNOSTICS
10.15.1 BUSINESS OVERVIEW
10.15.2 PRODUCTS OFFERED
10.16 SA SCIENTIFIC, LTD.
10.16.1 BUSINESS OVERVIEW
10.16.2 PRODUCTS OFFERED
10.17 ALTONA DIAGNOSTICS GMBH
10.17.1 BUSINESS OVERVIEW
10.17.2 PRODUCTS OFFERED
10.18 CORIS BIOCONCEPT SPRL
10.18.1 BUSINESS OVERVIEW
10.18.2 PRODUCTS OFFERED
10.19 ELITECH GROUP
10.19.1 BUSINESS OVERVIEW
10.19.2 PRODUCTS OFFERED
10.20 MAST GROUP LTD.
10.20.1 BUSINESS OVERVIEW
10.20.2 PRODUCTS OFFERED
10.21 RIGHT-TO-WIN

11 APPENDIX (Page No. – 121)
11.1 DISCUSSION GUIDE
11.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
11.3 AVAILABLE CUSTOMIZATIONS
11.4 RELATED REPORTS
11.5 AUTHOR DETAILS

LIST OF TABLES (102 Tables)

TABLE 1 INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2018–2025 (USD MILLION)
TABLE 2 TRADITIONAL DIAGNOSTIC TESTS MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 3 NORTH AMERICA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 4 EUROPE: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 5 ASIA PACIFIC: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 6 TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 7 RIDT MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 8 NORTH AMERICA: RIDT MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 9 EUROPE: RIDT MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 10 VIRAL CULTURE MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 11 NORTH AMERICA: VIRAL CULTURE MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 12 EUROPE: VIRAL CULTURE MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 13 DFA MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 14 NORTH AMERICA: DFA MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 15 EUROPE: DFA MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 16 SEROLOGICAL ASSAYS MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 17 NORTH AMERICA: SEROLOGICAL ASSAYS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 18 EUROPE: SEROLOGICAL ASSAYS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 19 MOLECULAR DIAGNOSTIC TESTS MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 20 NORTH AMERICA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 21 EUROPE: MOLECULAR DIAGNOSTIC TESTS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 22 ASIA PACIFIC: MOLECULAR DIAGNOSTIC TESTS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 23 MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 24 RT-PCR MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 25 NORTH AMERICA: RT-PCR MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 26 EUROPE: RT-PCR MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 27 INAAT MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 28 NORTH AMERICA: INAAT MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 29 EUROPE: INAAT MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 30 INAAT MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 31 TMA ASSAYS MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 32 NORTH AMERICA: TMA ASSAYS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 33 LAMP ASSAYS MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 34 NORTH AMERICA: LAMP ASSAYS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 35 NASBA TESTS MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 36 NORTH AMERICA: NASBA TESTS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 37 OTHER INAAT TESTS MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 38 NORTH AMERICA: OTHER INAAT TESTS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 39 OTHER MOLECULAR TESTS MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 40 NORTH AMERICA: OTHER MOLECULAR TESTS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 41 EUROPE: OTHER MOLECULAR TESTS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 42 INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 43 INFLUENZA DIAGNOSTICS MARKET FOR HOSPITALS, BY REGION, 2018–2025 (USD MILLION)
TABLE 44 NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 45 EUROPE: INFLUENZA DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 46 INFLUENZA DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY REGION, 2018–2025 (USD MILLION)
TABLE 47 NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 48 EUROPE: INFLUENZA DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 49 INFLUENZA DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2018–2025 (USD MILLION)
TABLE 50 NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 51 EUROPE: INFLUENZA DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 52 INFLUENZA DIAGNOSTICS MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 53 INFLUENZA DIAGNOSTICS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 54 NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 55 NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2018–2025 (USD MILLION)
TABLE 56 NORTH AMERICA: TRADITIONAL DIAGNOSTICS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 57 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 58 NORTH AMERICA: INAAT MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 59 NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 60 US: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2018–2025 (USD MILLION)
TABLE 61 US: TRADITIONAL DIAGNOSTICS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 62 US: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 63 US: INAAT MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 64 US: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 65 CANADA: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2018–2025 (USD MILLION)
TABLE 66 CANADA: TRADITIONAL DIAGNOSTICS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 67 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 68 CANADA: INAAT MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 69 CANADA: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 70 EUROPE: INFLUENZA DIAGNOSTICS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 71 EUROPE: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2018–2025 (USD MILLION)
TABLE 72 EUROPE: TRADITIONAL DIAGNOSTICS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 73 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 74 EUROPE: INAAT MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 75 EUROPE: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 76 FRANCE: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2018–2025 (USD MILLION)
TABLE 77 FRANCE: TRADITIONAL DIAGNOSTICS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 78 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 79 FRANCE: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 80 UK: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2018–2025 (USD MILLION)
TABLE 81 UK: TRADITIONAL DIAGNOSTICS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 82 UK: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 83 UK: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 84 ROE: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2018–2025 (USD MILLION)
TABLE 85 ROE: TRADITIONAL DIAGNOSTICS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 86 ROE: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 87 ROE: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 88 ASIA PACIFIC: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2018–2025 (USD MILLION)
TABLE 89 ASIA PACIFIC: TRADITIONAL DIAGNOSTICS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 90 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 91 ASIA PACIFIC: INAAT MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 92 ASIA PACIFIC: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 93 ASIA PACIFIC: INFLUENZA DIAGNOSTICS MARKET, BY COUNTRY/REGION, 2018–2025 (USD MILLION)
TABLE 94 CHINA: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2018–2025 (USD MILLION)
TABLE 95 JAPAN: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2018–2025 (USD MILLION)
TABLE 96 INDIA: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2018–2025 (USD MILLION)
TABLE 97 ROAPAC: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2018–2025 (USD MILLION)
TABLE 98 ROW: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2018–2025 (USD MILLION)
TABLE 99 ROW: TRADITIONAL DIAGNOSTICS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 100 ROW: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 101 ROW: INAAT MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 102 ROW: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2018–2025 (USD MILLION)

LIST OF FIGURES (34 Figures)

FIGURE 1 BREAKDOWN OF PRIMARIES: INFLUENZA DIAGNOSTICS MARKET
FIGURE 2 DATA TRIANGULATION METHODOLOGY
FIGURE 3 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE-BASED ESTIMATION)
FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 2 (TEST TYPE-BASED ESTIMATION)
FIGURE 5 INFLUENZA DIAGNOSTICS MARKET: CAGR PROJECTIONS
FIGURE 6 INFLUENZA DIAGNOSTICS MARKET: CAGR PROJECTIONS FROM THE ANALYSIS OF DEMAND-SIDE DRIVERS, OPPORTUNITIES, RESTRAINTS, & CHALLENGES
FIGURE 7 INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2019
FIGURE 8 INFLUENZA DIAGNOSTIC MARKET, BY END USER, 2019 VS. 2025
FIGURE 9 GEOGRAPHICAL SNAPSHOT OF THE INFLUENZA DIAGNOSTIC MARKET
FIGURE 10 INCREASING PREVALENCE OF INFLUENZA TO DRIVE MARKET GROWTH
FIGURE 11 TRADITIONAL DIAGNOSTIC TESTS TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICAN INFLUENZA DIAGNOSTIC MARKET IN 2019
FIGURE 12 HOSPITALS DOMINATED THE INFLUENZA DIAGNOSTICS MARKET IN 2019
FIGURE 13 INFLUENZA DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 14 IMPACT OF THE COVID-19 OUTBREAK ON THE GROWTH OF THE INFLUENZA DIAGNOSTICS MARKET
FIGURE 15 INFLUENZA DIAGNOSTICS MARKET: GEOGRAPHIC SNAPSHOT (2019)
FIGURE 16 PERCENTAGE SHARE OF INFLUENZA SPECIMEN TESTED, BY REGION (2019)
FIGURE 17 NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET SNAPSHOT, 2019
FIGURE 18 ASIA PACIFIC: INFLUENZA DIAGNOSTICS MARKET SNAPSHOT
FIGURE 19 RANK OF COMPANIES IN THE INFLUENZA DIAGNOSTICS MARKET, 2019
FIGURE 20 INFLUENZA DIAGNOSTICS MARKET (GLOBAL) GLOBAL COMPETITIVE LEADERSHIP MAPPING, 2019
FIGURE 21 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT
FIGURE 22 QUIDEL CORPORATION: COMPANY SNAPSHOT
FIGURE 23 COMPANY SNAPSHOT: THERMO FISHER SCIENTIFIC, INC.
FIGURE 24 COMPANY SNAPSHOT: ABBOTT LABORATORIES, INC.
FIGURE 25 HOLOGIC, INC.: COMPANY SNAPSHOT
FIGURE 26 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT
FIGURE 27 DANAHER CORPORATION: COMPANY SNAPSHOT
FIGURE 28 DIASORIN SA: COMPANY SNAPSHOT
FIGURE 29 MERIDIAN BIOSCIENCE: COMPANY SNAPSHOT
FIGURE 30 LUMINEX CORPORATION: COMPANY SNAPSHOT
FIGURE 31 BIOMÉRIEUX SA: COMPANY SNAPSHOT
FIGURE 32 GENMARK DIAGNOSTICS, INC.: COMPANY SNAPSHOT
FIGURE 33 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT
FIGURE 34 TECAN TRADING: COMPANY SNAPSHOT



★調査レポート[インフルエンザ診断の世界市場予測:テスト種類別(分子型(RT-PCR、LAMP、NASBA)、従来型(ウイルス培養、直接蛍光抗体、インフルエンザ迅速検査、血清アッセイ))、エンドユーザー別(病院、臨床検査室)] ( Influenza Diagnostics Market by Test type (Molecular (RT-PCR,LAMP, NASBA), Traditional (Viral Culture, Direct Fluorescent Antibody, Rapid Influenza Detection Tests, Serological Assays)), End user (Hospital, Clinical Laboratories) - Global Forecast to 2025 / BT 5027) 販売に関する免責事項
[インフルエンザ診断の世界市場予測:テスト種類別(分子型(RT-PCR、LAMP、NASBA)、従来型(ウイルス培養、直接蛍光抗体、インフルエンザ迅速検査、血清アッセイ))、エンドユーザー別(病院、臨床検査室)] ( Influenza Diagnostics Market by Test type (Molecular (RT-PCR,LAMP, NASBA), Traditional (Viral Culture, Direct Fluorescent Antibody, Rapid Influenza Detection Tests, Serological Assays)), End user (Hospital, Clinical Laboratories) - Global Forecast to 2025 / BT 5027) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆